Evaluation of Thrombosis-related Biomarkers Before and After Therapy in Patients with Multiple Myeloma

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2018 Feb 7

PMID 29403323

Citations 10

Authors

Shosaku Nomura

Tomoki Ito

Hideaki Yoshimura

Masaaki Hotta

Takahisa Nakanishi

Shinya Fujita

Aya Nakaya

Atsushi Satake

Kazuyoshi Ishii

Affiliations

Soon will be listed here.

Abstract

Background: Thrombosis is one of the complications in the clinical course of multiple myeloma (MM). Vascular endothelial cells and/or the hemostatic-coagulatory system are thought to play an important role in thrombosis of MM. In addition to melphalan-prednisone (Mel-P) therapy, several new therapeutic drugs such as lenalidomide or bortezomib have been developed and show effectiveness against MM. However, these new drugs also have risk of therapy-related thrombosis.

Methods: We assessed 103 MM patients and 30 healthy controls, using enzyme-linked immunosorbent assays to evaluate five biomarkers: platelet-derived microparticles (PDMP), plasminogen activator inhibitor-1 (PAI-1), high mobility group box protein-1 (HMGB1), endothelial protein C receptor (EPCR), and soluble vascular cell adhesion molecule-1 (sVCAM-1). The effects of Mel-P, bortezomib, and lenalidomide on the plasma concentrations of these biomarkers were investigated.

Results: The plasma concentrations of PDMP, PAI-1, HMGB1, EPCR, and sVCAM-1 were higher in MM patients than in healthy controls. Mel-P, bortezomib, and lenalidomide therapies all reduced biomarker levels after treatment. However, when only patients with higher levels of EPCR were compared, differences were seen between the three therapies in the elevation of PDMP, HMGB1, and PAI-1.

Conclusion: These results suggest that both MM and therapies for MM can induce a hypercoagulable state. The elevated risk of thrombosis conferred by hypercoagulability increases patient morbidity and mortality. Attention should be paid to therapy-related thrombosis when new therapeutic regimens are selected for MM patients.

Citing Articles

Rediscovering hemostasis abnormalities in multiple myeloma: The new era.

Huang Y, Wang C, Wang H, Liu H, Zhou L Heliyon. 2024; 10(13):e34111.

PMID: 39055831 PMC: 11269926. DOI: 10.1016/j.heliyon.2024.e34111.

Effects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple Myeloma.

Geduk A, Oztas B, Eryilmaz B, Terzi Demirsoy E, Menguc M, Unal S Indian J Hematol Blood Transfus. 2023; 39(2):220-227.

PMID: 37006982 PMC: 10064350. DOI: 10.1007/s12288-022-01574-6.

Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.

Li H, Roy M, Liang L, Cao W, Hu B, Li Y Oncogene. 2022; 41(9):1298-1308.

PMID: 34997217 DOI: 10.1038/s41388-021-02167-9.

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.

Yuan S, Liu Z, Xu Z, Liu J, Zhang J J Hematol Oncol. 2020; 13(1):91.

PMID: 32660524 PMC: 7359022. DOI: 10.1186/s13045-020-00920-3.

Mechanisms and biomarkers of cancer-associated thrombosis.

Kim A, Khorana A, McCrae K Transl Res. 2020; 225():33-53.

PMID: 32645431 PMC: 8020882. DOI: 10.1016/j.trsl.2020.06.012.

References

Ducros E, Mirshahi S, Faussat A, Mirshahi P, Dimicoli S, Tang R . Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies. Cancer Med. 2013; 1(2):261-7. PMC: 3544449. DOI: 10.1002/cam4.11. View

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

Martinez-Lopez J, Blade J, Mateos M, Grande C, Alegre A, Garcia-Larana J . Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011; 118(3):529-34. DOI: 10.1182/blood-2011-01-332320. View

Leebeek F, Kruip M, Sonneveld P . Risk and management of thrombosis in multiple myeloma. Thromb Res. 2012; 129 Suppl 1:S88-92. DOI: 10.1016/S0049-3848(12)70024-5. View

Wang X, Li Y, Yan X . Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis. Biomed Res Int. 2016; 2016:6848902. PMC: 4753325. DOI: 10.1155/2016/6848902. View

Maiga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S . Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. Br J Cancer. 2013; 108(9):1801-6. PMC: 3658519. DOI: 10.1038/bjc.2013.186. View

Mackman N . New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012; 122(7):2331-6. PMC: 3386811. DOI: 10.1172/JCI60229. View

Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y . Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost. 2003; 89(3):506-12. View

Castellino F, Ploplis V . The protein C pathway and pathologic processes. J Thromb Haemost. 2009; 7 Suppl 1:140-5. PMC: 3669675. DOI: 10.1111/j.1538-7836.2009.03410.x. View

10.

Chong B, Lee S . Management of thromboembolism in hematologic malignancies. Semin Thromb Hemost. 2007; 33(4):435-48. DOI: 10.1055/s-2007-976179. View

11.

Palumbo A, Rajkumar S, Dimopoulos M, Richardson P, San Miguel J, Barlogie B . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2007; 22(2):414-23. DOI: 10.1038/sj.leu.2405062. View

12.

Auwerda J, Yuana Y, Osanto S, de Maat M, Sonneveld P, Bertina R . Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2010; 105(1):14-20. DOI: 10.1160/TH10-03-0187. View

13.

Fayers P, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M . Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011; 118(5):1239-47. DOI: 10.1182/blood-2011-03-341669. View

14.

Su C, Liu Y, Yang C, Lin Y, Chiou J, Chi L . Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer. PLoS One. 2015; 10(7):e0133411. PMC: 4521958. DOI: 10.1371/journal.pone.0133411. View

15.

Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D . The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary.... BMC Hematol. 2016; 16:14. PMC: 4869302. DOI: 10.1186/s12878-016-0053-9. View

16.

Fleitas T, Martinez-Sales V, Vila V, Reganon E, Mesado D, Martin M . Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One. 2012; 7(10):e47365. PMC: 3471832. DOI: 10.1371/journal.pone.0047365. View

17.

Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y . Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost. 2001; 85(2):326-30. View

18.

Davies F, Wu P, Jenner M, Srikanth M, Saso R, Morgan G . The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007; 92(8):1149-50. DOI: 10.3324/haematol.11228. View

19.

Franchini M, Di Minno M, Coppola A . Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost. 2010; 36(4):388-403. DOI: 10.1055/s-0030-1254048. View

20.

Rajkumar S, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M . Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2009; 11(1):29-37. PMC: 3042271. DOI: 10.1016/S1470-2045(09)70284-0. View